Notes:
• Dapagliflozin is a mildly effective hypoglycemic with diuretic properties. It has shown benefit in reducing hospitalizations of type 2 diabetes patients with heart failure.

Initiation (new start) criteria: Non-formulary Dapagliflozin (Farxiga) will be covered on the prescription drug benefit when the following criteria are met:
• Diagnosis of type 2 diabetes, and
• Intolerance* to preferred SGLT-2 inhibitor empagliflozin (Jardiance) which is also CBC, and
• Patient has a recent HbA1c under 8.5, and
• On maximally tolerated metformin dose (1500-2500mg) for at least 3 months (or allergy or intolerance* to metformin), and
• Heart Failure
  a. And on maximally tolerated dose or patient has an allergy or intolerance* to statin
  b. And on maximally tolerated dose or patient has an allergy or intolerance* to ACE/ARB
  c. And on maximally tolerated dose or patient has an allergy or intolerance* to beta blocker

* Intolerance excludes adverse drug reactions that are expected, mild in nature, resolve with continued treatment, and do not require medication discontinuation